Abstract
The potential role of unrelated donor cord blood transplantation (UD-CBT) in adults is not well established. We report the results of UD-CBT in nine adult patients with chronic myeloid leukemia (CML). The median age was 27 years (range, 19–41 years), and the median weight was 62 kg (range, 45–78 kg). At transplant, six patients were in chronic phase (five in first, and one in second), two in blast crisis, and one in accelerated phase. Eight had received intensive chemotherapy, and three had undergone autologous peripheral blood hematopoietic stem cell transplantation. Four had received interferon with no cytogenetic response, and only three underwent UD-CBT within 1 year of diagnosis. After serological typing for class I antigens, and high-resolution DNA typing for DRB1, the degree of HLA match between patients and cord blood (CB) units was 4/6 in six cases and 5/6 in three cases. The median number of nucleated cells infused was 1.7 × 107/kg (range, 1.2 to 4.9 × 107/kg), and was above 2 × 107/kg in only two cases. All patients received thiotepa, busulfan, cyclophosphamide and anti-thymocyte globulin as conditioning; cyclosporine and prednisone for graft-versus-host disease (GVHD) prophylaxis; and G-CSF from day +7 until engraftment. All seven evaluable cases engrafted. The median time to reach an absolute neutrophil count ⩾0.5 × 109/l and ⩾1 × 109/l was 22 days (range, 19–52 days) and 28 days (range, 23–64 days), respectively. In the four patients evaluable for platelet recovery time to levels of ⩾20 × 109 platelets/l, ⩾50 × 109 platelets/l, and ⩾100 × 109 platelets/l, these ranged from 50 to 128 days, 60 to 139 days, and 105 to 167 days, respectively. Three patients developed acute GVHD above grade II, and three of the five patients at risk developed extensive chronic GVHD. Four patients, all transplanted in chronic phase, remain alive in molecular remission more than 18, 19, 24 and 42 months after transplantation. These preliminary results suggest that UD-CBT may be considered a reasonable alternative in adults with CML who lack an appropriate bone marrow donor. Bone Marrow Transplantation (2001) 27, 693–701.
Similar content being viewed by others
References
Chronic Myeloid Leukemia Trialists’ Collaborative Group . Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials J Natl Cancer Inst 1997 89: 1616–1620
Guilhot F, Chastang C, Michallet M et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group New Engl J Med 1997 337: 223–229
Kurzrock R, Estrov Z, Kantarjian H, Talpaz M . Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity J Clin Oncol 1998 16: 1526–1531
Druker BJ, Talpaz M, Resta D et al. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia Blood 1999 94: (Suppl. 1) 368a
Druker BJ, Lydon NB . Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myeloid leukemia J Clin Invest 2000 105: 3–7
Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia Ann Intern Med 1986 104: 155–163
Goldman J, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia New Engl J Med 1986 314: 202–207
Sawyers CL . Chronic myeloid leukemia New Engl J Med 1999 340: 1330–1340
Faderl S, Talpaz M, Estrov Z, Kantarjian HM . Chronic myelogenous leukemia: biology and therapy Ann Intern Med 1999 131: 207–219
Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia New Engl J Med 1998 338: 962–968
McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the National Marrow Donor Program Blood 2000 95: 2219–2225
Kurtzberg J, Laughlin M, Graham MC et al. Placental blood as source of hematopoietic stem cells for transplantation into unrelated recipients New Engl J Med 1996 335: 157–166
Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group New Engl J Med 1997 337: 373–381
Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord-blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease Blood 1996 88: 795–802
Cairo MS, Wagner JE . Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation Blood 1997 90: 4665–4678
Rubinstein P, Carrier C, Scaradavou M et al. Outcome among 562 recipients of placental blood transplants from unrelated donors New Engl J Med 1998 339: 1565–1577
Rocha V, Wagner JE, Sobocinski KA et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling New Engl J Med 2000 342: 1846–1854
Rocha V, Cornish J, Sievers E et al. Comparison of the outcome of unrelated bone marrow (BM) or cord blood (CB) transplants in children with acute leukemia (AL) Blood 1999 94: (Suppl. 1) 712a
Laporte JP, Gorin NC, Rubinstein P et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia New Engl J Med 1996 335: 167–170
Pecora AL, Stiff P, Jennis A et al. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood Bone Marrow Transplant 2000 25: 797–799
Long G, Madan B, Kurtzberg J et al. Unrelated umbilical cord blood transplants in adult patients (PTS) with hematological malignancies or genetic disorders Blood 1999 94: (Suppl. 1) 570a
Terasaki PI, McLelland J . Microdroplet assay of human serum cytoxins Nature 1964 204: 988–1000
Olerup O, Zetterquist H . HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor–recipient matching in cadaveric transplantation Tissue Antigens 1992 39: 225–235
Buyse I, Decorte R, Cuppens H et al. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization Tissue Antigens 1993 41: 1–14
Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution Proc Natl Acad Sci USA 1995 92: 10119–10122
Miller SA, Dykes DD, Polesky HF . A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 1988 16: 1215
Boerwinkle E, Xiong W, Fourest E, Chan L . Rapid typing of tandemly repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein B 3′ hypervariable region Proc Natl Acad Sci USA 1989 86: 212–216
Budowle B, Chakraborty R, Giusti AM et al. Analysis of the VNTR locus D1S80 by PCR followed by high resolution PAGE Am J Hum Genet 1991 48: 137–144
Richards B, Heilig R, Oberle I et al. Rapid PCR analysis of the St14 (DXS52) VNTR Nucleic Acids Res 1991 19: 1944
Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 1987 162: 156–159
Cross NC, Hughes TP, Feng L et al. Minimal residual disease after allogenic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft-versus-host disease and relapse Br J Haematol 1993 84: 67–74
Gluckman E, Broxmeyer HE, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling New Engl J Med 1989 321: 1174–1178
Wagner JE, Kernan NA, Steinvuch M et al. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease Lancet 1995 346: 214–219
Lambertenghi Deliliers G, Soligo D, Della Volpe A et al. Unrelated mismatched cord blood transplantation in an adult with secondary AML Bone Marrow Transplant 1996 18: 469–472
Gonzalez Barca E, Querol S, Grañena A et al. Umbilical cord blood transplantation from an unrelated donor in an adult weighing 90 kilograms. Role of immunosuppression in engraftment Bone Marrow Transplant 1997 20: 333–336
Laughlin MJ, Rizzieri DA, Smith CA et al. Hematologic engraftment and reconstitution of immune function post unrelated placental cord blood transplant in an adult with acute lymphocytic leukemia Leukemia Res 1998 22: 215–219
Gian VG, Moreb JS, Abdel-Mageed A et al. Successful salvage using mismatched umbilical cord blood transplant in an adult with recurrent acute myelogenous leukemia failing autologous peripheral blood progenitor cell transplant: a case history and review Bone Marrow Transplant 1998 21: 1197–1200
Rocha V, Arcese W, Sanz G et al. Prognostic factors of outcome after unrelated cord blood transplant (UCBT) in adults with hematologic malignancies Blood 2000 96: (Suppl. 1) 587a
Kurtzberg J, Laughlin MJ, Smith CA et al. Hematopoietic recovery in adult recipients following unrelated umbilical cord blood transplantation Blood 1997 90: (Suppl. 1) 480a
Migliaccio AR, Adamson JW, Stevens CE et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity Blood 2000 96: 2717–2722
Locatelli F, Rocha V, Chastang C et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord Cord Blood Transplant Group Blood 1999 93: 3662–3671
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sanz, G., Saavedra, S., Jiménez, C. et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplant 27, 693–701 (2001). https://doi.org/10.1038/sj.bmt.1702878
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702878
- Springer Nature Limited
Keywords
This article is cited by
-
Management of Advanced-Phase Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports (2015)
-
Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis
International Journal of Hematology (2014)
-
Does Mesenchymal Stem Cell Population in Umbilical Cord Blood Vary at Different Gestational Periods?
The Indian Journal of Pediatrics (2013)
-
Role of allo-SCT for CML in 2010
Bone Marrow Transplantation (2010)
-
Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase
Bone Marrow Transplantation (2008)